Cox-2 inhibition can lead to adverse effects in a rat model for temporal lobe epilepsy

Epilepsy Research

Volumn 91, Issue 1, 2010, Pages 49-56

  Holtman, Linda ^a   Van Vliet, Erwin A ^a,b   Edelbroek, Peter M ^b   Aronica, Eleonora ^c   Gorter, Jan A ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Neuroinflammation; P glycoprotein; Pharmacoresistance; Status epilepticus; Temporal lobe epilepsy

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CYCLOOXYGENASE 2; PHENYTOIN;

ADVERSE OUTCOME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; ELECTROENCEPHALOGRAPHY; ENZYME INHIBITION; EPILEPTIC STATE; EPILEPTOGENESIS; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE THRESHOLD; TEMPORAL LOBE EPILEPSY; TREATMENT DURATION;

ANIMALS; CHRONIC DISEASE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; ELECTROENCEPHALOGRAPHY; EPILEPSY, TEMPORAL LOBE; MALE; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 77956010858     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2010.06.011     Document Type: Article

References (26)

1. Baik E.J., Kim E.J., Lee S.H., Moon C. Cyclooxygenase-2 selective inhibitors aggravate kainic acid induced seizure and neuronal cell death in the hippocampus. Brain Res. 1999, 843:118-129.
2. Bauer B., Hartz A.M., Pekcec A., Toellner K., Miller D.S., Potschka H. Seizure-induced up-regulation of P-glycoprotein at the blood-brain barrier through glutamate and cyclooxygenase-2 signaling. Mol. Pharmacol. 2008, 73:1444-1453.
3. Cavazos J.E., Golarai G., Sutula T.P. Septotemporal variation of the supragranular projection of the mossy fiber pathway in the dentate gyrus of normal and kindled rats. Hippocampus 1992, 2:363-372.
4. Gorter J.A., van Vliet E.A., Aronica E., Lopes da Silva F.H. Progression of spontaneous seizures after status epilepticus is associated with mossy fibre sprouting and extensive bilateral loss of hilar parvalbumin and somatostatin-immunoreactive neurons. Eur. J. Neurosci. 2001, 13:657-669.
5. Gorter J.A., van Vliet E.A., Aronica E., Breit T., Rauwerda H., Lopes da Silva F.H., Wadman W.J. Potential new anti-epileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J. Neurosci. 2006, 26:11083-11110.
6. Govoni S., Masoero E., Favalli L., Rozza A., Scelsi R., Viappiani S., Buccellati C., Sala A., Folco G. The cycloxygenase-2 inhibitor SC58236 is neuroprotective in an in vivo model of focal ischemia in the rat. Neurosci. Lett. 2001, 303:91-94.
7. Hewett S.J., Silakova J.M., Hewett J.A. Oral treatment with rofecoxib reduces hippocampal excitotoxic neurodegeneration. J. Pharmacol. Exp. Ther. 2006, 319:1219-1224.
8. Holtman L., van Vliet E.A., van Schaik R., Queiroz C.M., Aronica E., Gorter J.A. Effects of SC58236, a selective COX-2 inhibitor, on epileptogenesis and spontaneous seizures in a rat model for temporal lobe epilepsy. Epilepsy Res. 2009, 84:56-66.
9. Iadecola C., Niwa K., Nogawa S., Zhao X., Nagayama M., Araki E., Morham S., Ross M.E. Reduced susceptibility to ischemic brain injury and N-methyl-d-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:1294-1299.
10. Jamali S., Bartolomei F., Robaglia-Schlupp A., Massacrier A., Peragut J.C., Regis J., Dufour H., Ravid R., Roll P., Pereira S., Royer B., Roeckel-Trevisiol N., Fontaine M., Guye M., Boucraut J., Chauvel P., Cau P., Szepetowski P. Large-scale expression study of human mesial temporal lobe epilepsy: evidence for dysregulation of the neurotransmission and complement systems in the entorhinal cortex. Brain 2006, 129:625-641.
11. Jung K.H., Chu K., Lee S.T., Kim J., Sinn D.I., Kim J.M., Park D.K., Lee J.J., Kim S.U., Kim M., Lee S.K., Roh J.K. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol. Dis. 2006, 23:237-246.
12. Kim H.J., Chung J.I., Lee S.H., Jung Y.S., Moon C.H., Baik E.J. Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors. Brain Res. 2008, 1193:153-161.
13. Kunz T., Oliw E.H. The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainate-induced cell death in the rat hippocampus. Eur. J. Neurosci. 2001, 13:569-575.
14. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates, San Diego 1998.
15. Pekcec A., Unkruer B., Schlichtiger J., Soerensen J., Hartz A.M., Bauer B., van Vliet E.A., Gorter J.A., Potschka H. Targeting prostaglandin E2 EP1 receptors prevents seizure-associated P-glycoprotein up-regulation. J. Pharmacol. Exp. Ther. 2009, 330:939-947.
16. Racine R.J. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972, 32:281-294.
17. Ravizza T., Gagliardi B., Noe F., Boer K., Aronica E., Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol. Dis. 2008, 29:142-160.
18. Simmons D.L., Botting R.M., Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol. Rev. 2004, 56:387-437.
19. van Vliet E.A. The Role of the Blood-Brain Barrier and Multidrug Transporters in Pharmacoresistant Epilepsy 2007, Center for Neuroscience, University of Amsterdam, Amsterdam.
20. van Vliet E.A., Aronica E., Redeker S., Marchi N., Rizzi M., Vezzani A., Gorter J.A. Selective and persistent upregulation of mdr1b mRNA and P-glycoprotein in the parahippocampal cortex of chronic epileptic rats. Epilepsy Res. 2004, 60:203-213.
21. van Vliet E.A., Aronica E., Tolner E.A., Lopes da Silva F.H., Gorter J.A. Progression of temporal lobe epilepsy in the rat is associated with immunocytochemical changes in inhibitory interneurons in specific regions of the hippocampal formation. Exp. Neurol. 2004, 187:367-379.
22. van Vliet E.A., Van Schaik R., Edelbroek P.M., Redeker S., Aronica E., Wadman W.J., Marchi N., Vezzani A., Gorter J.A. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006, 47:672-680.
23. van Vliet E.A., van Schaik R., Edelbroek P.M., Lopes da Silva F.H., Wadman W.J., Gorter J.A. Development of tolerance to levetiracetam in rats with chronic epilepsy. Epilepsia 2008, 49:1151-1159.
24. van Vliet E.A., Zibell G., Pekcec A., Schlichtiger J., Edelbroek P.M., Holtman L., Aronica E., Gorter J.A., Potschka H. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 2010, 58:404-412.
25. Vezzani A., Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005, 46:1724-1743.
26. Zibell G., Unkruer B., Pekcec A., Hartz A.M., Bauer B., Miller D.S., Potschka H. Prevention of seizure-induced up-regulation of endothelial P-glycoprotein by COX-2 inhibition. Neuropharmacology 2009, 56:849-855.